Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in the Journal of Molecular Biology (JMB).
The publication, titled, "High-resolution Cryo-EM Analysis of the Therapeutic Pseudomonas Phage Pa223," describes the structure of phage Pa223, which is included in Armata's five-phage clinical cocktail, AP-PA02. Armata is developing AP-PA02 as a potential treatment for chronic respiratory infections in people with cystic fibrosis and non-cystic fibrosis bronchiectasis (NCFB). AP-PA02 has shown promising results in two Phase 2 clinical trials to date - SWARM-P.a. and Tailwind.
Posted In: ARMP